Business News • PR NewsWire • New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol

New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol

New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol

THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant...

View More : http://www.prnewswire.com/news-releases/new-detailed-data-from-three-phase-3-pivotal-studies-show-amgens-novel-investiga...

Releted News by prnewswire

Private Coaching Sessions From Scott Tucker

LED Canopy Light from Access Fixtures Reaches New Low Price

Container Manufacturing & Transportation Industry in China with 2018 Forecasts

Global Guardian Adds Somalia To Service Area

Turfing Vendor Market: Small Cells Towers for Wireless Infrastructure Coverage Analysis

La conférence UAV Payloads : une première absolue